Hemangiomas – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hemangiomas – Drugs In Development, 2024 report and make more profitable business decisions.
Hemangiomas are the most common benign tumors in infants also known as strawberry marks. It is a non-cancerous vascular tumors caused by endothelial cell proliferation. Strawberry like birth marks appears on the skin within one to three weeks after the birth in around 4-5% of newborns. Most of the hemangiomas subsides without treatment and mostly occurs in premature infants. Superficial hemangioma, deep hemangioma, and combination of both are the three types of hemangiomas. Physical examination of the skin, biopsy tests and laboratory examination to evaluate the levels of GLUT 1 and imaging studies MRI, CT scan are done. As the condition gets subsided on its own no treatment is necessary but in complicated cases beta blockers, oral prednisone with drug adjustment and oral and topical corticosteroids.
The Hemangiomas drugs in development market research report provide comprehensive information on the therapeutics under development for Hemangiomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemangiomas and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hemangiomas | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hemangiomas therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hemangiomas pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hemangiomas treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AFT Pharmaceuticals LtdArkayli Biopharma Inc
Aucta Pharmaceuticals LLC
Cervello Therapeutics Inc
Eisai Co Ltd
FIRC Institute of Molecular Oncology
Graviton Bioscience Corp
Neurelis Inc
Recursion Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Sichuan Aobanggood Pharmaceutical Co Ltd
University of California San Diego
Wuhan Kefu New Drug Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hemangiomas reports